Part II: Risk stratification in patients with unstable angina and non-ST segment elevation myocardial infarction: Evidence-based review

Journal of Invasive Cardiology

Volumn 14, Issue 5, 2002, Pages 254-262

  Doukky, Rami ^a,b   Calvin, James E ^a,b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TIROFIBAN;

ALGORITHM; DEATH; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; Q WAVE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ALGORITHMS; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; HEMATOLOGIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; RISK ASSESSMENT; TROPONIN;

EID: 0036246997     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndrome: A TIMI 11A substudy. Thrombolysis in Myocardial Infarction
2. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI-11B substudy
3. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
4. The efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events (ESSENCE) study group: A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
5. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis
6. The CAPTURE Investigators: Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
7. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-plus) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
8. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
9. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
10. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
11. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemic syndrome management
12. Thrombolysis in Myocardial Ischemia TIMI-IIIB investigators: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia
13. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy
14. Fragmin and Fast Revascularization During Instability in Coronary Artery Disease Investigators: Invasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicenter study
15. TACTICS - Thrombolysis in Myocardial Infarction (TIMI) 18 Investigators: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
16. The TIMI risk score for unstable angina/non-ST-elevation MI: A method for prognostication and therapeutic decision making
17. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance
18. Prior aspirin use predicts worse outcome in patients with non-ST-elevation acute coronary syndrome. PURSUIT Investigators. Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
19. Prior aspirin use in a univariate, but not a multivariate predictor of 1 year mortality in 10,302 patients with acute coronary syndromes: Results from OPUS-TIMI 16
20. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients
21. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS
22. Long-term prognosis in unstable angina. The importance of early risk stratification us continuous ST-segment monitoring
23. The combination of a continuous 12-lead ECG and troponin T. A valuable tool for risk stratification during the first 6 hours in patients with chest pain and nondiagnostic ECG
24. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events: Meta-analysis of three studies involving 995 patients
25. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: Relation with death and myocardial infarction. PURSUIT ECGIschemia Monitoring Substudy Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
26. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease
27. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
28. Long-term effects of pravastatin on plasma concentration of C-reactive protein
29. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
30. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACLE study: A randomized controlled trial
31. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
32. The prognostic value of B-Type natriuretic peptide in patient with acute coronary syndromes
33. Understanding articles describing clinical prediction tools
34. Defining risk in unstable angina: Current trial design does not tell us who should be treated and with what therapy
35. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina
36. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study
37. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes
38. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
39. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization